Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358307 | 0.80 | MAPK14 (0.69) | MAPK14 | |
| SCHEMBL4551051 | 0.66 | FPR2 (0.43) | AXL | |
| SCHEMBL4551588 | 0.60 | FPR2 (0.39) | CCNB2CCNE2CDK1CCNB1CCNE1 | |
| SCHEMBL22573136 | 0.56 | MAPK1 (0.46) | — | |
| SCHEMBL1311852 | 0.56 | MAPK14 (0.70) | MAPK14 | |
| SCHEMBL16341545 | 0.56 | ALDH1A1 (0.46) | — | |
| SCHEMBL16341708 | 0.56 | ALDH1A1 (0.42) | MAPK14CCNB2CCNE2CDK1CCNB1 | |
| SCHEMBL3422561 | 0.55 | LMNA (0.38) | AXL | |
| SCHEMBL22573037 | 0.55 | KAT2B (0.50) | — | |
| SCHEMBL29901795 | 0.55 | BRD4 (0.55) | AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420649-B2 | Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof | AMGEN INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420649-B2 | Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof | AMGEN INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2010025202-A1 | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281864-A1 | Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof | MAPK1, MAPK3, MAP4K2 | MAPK14 38/4885CCNB2 388/4885CCNE2 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.